

|    |   |  |   |
|----|---|--|---|
| 1  | Details of the person discharging managerial responsibilities   |  |   |
| a) | Name  | Harald Gurvin  |   |
| b) | Position  | Chief Financial Officer                                |   |
| 2  | Reason for notification   |  |   |
| a) | Initial notification/<br>Amendment  | Initial  |   |
| 3  | Details of issuer   |  |   |
| a) | Name  | Nykode Therapeutics ASA                                |   |
| b) | LEI   | 254900UKQHWYZJD22017                                   |   |
| 4  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |  |   |
| a) | Description of the financial instrument, type of instrument   | Shares in Nykode Therapeutics ASA (ISIN: NO0010714785) |   |
| b) | Nature of the transaction   | Acquisition of shares                                  |   |
| c) | Price(s) and volume(s)  | Price(s)<br>NOK 13.99<br>NOK 14.00                     | Volume(s)<br>3,057<br>6,943             |
| d) | Aggregated information<br>-Average price, aggregated volume and total amount  | Price<br>Volume<br>Total amount                        | NOK 13.9969<br>10,000<br>NOK 139,969.43 |
| e) | Date of the transaction   | 13.03.2024   |   |
| f) | Place of the transaction  | XOSL - Oslo Stock Exchange                             |   |